Just one month after announcing a $66 billion pact to buy Allergan, Actavis is eyeing Spain's Almirall as a way to boost its European growth, according to Bloomberg.
2014 may have been a banner year in pharma M&A, but for companies looking to sell off their portfolios of aging meds, it wasn't quite big enough.
Novo Nordisk has a while yet to wait for another shot at FDA approval for Tresiba, a drug on which it has pinned its future, but it continues win support for it in Europe.
Orexigen has scored another big boost for its weight-loss drug, with a European drug advisory group giving it a recommendation for approval. The favorable review comes three months after the FDA approved it in the U.S., where it is already seeing some significant demand.
Salix is working quickly to get some inventory issues under control after bidding farewell to its CFO and launching an audit committee review. But as soon as it does, some shareholders want the North Carolina drugmaker to put itself on the block.
U.S. and Chinese trade officials announced on Thursday that China will streamline drug approvals and promised equal treatment of U.S. and Chinese companies in pricing probes.
Roche has been charting promising numbers for its standout breast cancer drugs Kadcyla and Perjeta. But now the next-gen duo has failed to beat Herceptin and chemo in a late-stage study, putting a damper on Roche's plan to expand the market for its new drugs and sending its shares into a downward spiral.
GlaxoSmithKline's shareholders may be expecting less-than-stellar sales next year as generics take their toll on respiratory behemoth Advair. But they still have plenty to look forward to, CEO Andrew Witty reminded them on Thursday.
GlaxoSmithKline rolled out data from a hefty Phase III study showing that its shingles-fighting candidate cut the risk of that disease by 97.2% in adults aged 50 and older, compared with placebo.
Armed with a $1.64 billion breakup fee from former merger partner AbbVie and a brand-new $2.1 billion revolving loan facility, Shire looks ready to strike a deal. Rumor says it's revisiting some of its old targets, including New Jersey's NPS Pharmaceuticals.
A far-reaching indictment against 14 New England Compounding Center (NECC) owners and employees not only accuses them of peddling unsterile drugs that infected hundreds of patients with fungal meningitis, but also includes 25 murder charges against two lead pharmacists.
AstraZeneca scored European approval for its ovarian cancer-treating drug Lynparza (olaparib), expanding its cancer portfolio at a time when the company is trying to show investors that it's better off independent.
As 2014 winds down, and Gilead Sciences keeps winding up hep C sales by the billion, AbbVie waits, vibrating with anticipation. Its three-drug cocktail is up for FDA approval any day now, and the Illinois-based company is ready to challenge Gilead for market share.
Last week, a New York judge called a halt on Actavis' plan to pull Namenda off the market, throwing off its strategy for switching patients to a newer extended-release version.
This week, the U.K. National Institute for Health and Care Excellence blessed Pfizer's kidney cancer treatment Inlyta, changed its mind in support of Bayer's prostate cancer therapy Xofigo, and backed Boehringer Ingelheim's anticoagulant Pradaxa for blood clots in the legs and lungs.
Not so fast, Teva. The generics giant--which last week said it was set to roll out copies of Pfizer blockbuster Celebrex--now has to put those plans on hold, as per a U.S. appeals court ruling.
After winning top reviews from the Harvard Business Review for his 2014 performance, Gilead Sciences CEO John Martin has picked up a "best CEO" nod from a Tuck School of Business prof. And the investing site Motley Fool puts him among the year's three "most exceptional" corporate chiefs.
Novartis has lashed out at India's Cipla in court for rolling out a deeply discounted generic of its COPD drug Onbrez without waiting for the courts to rule whether its patents are valid. It has sued Cipla for infringing its patents on Onbrez, known as Arcapta in the U.S.
Weeks after Belgium's UCB announced that it would sell its U.S. generic drug business for $1.53 billion, the company is calling off the sale in light of regulatory pushback over one of the unit's products.
When you tot up the billions of sales at risk of patent expiration in 2015, the result is $44 billion, the biggest number since the debacle of 2012. But in 2015, generics are expected to take a much smaller bite from the drugs losing exclusive access to their respective markets. That's because several of the big expiries involve biotech drugs.